Rosuvastatinum + Ezetimibum
Coroswera contains two different active substances. One of the active substances is rosuvastatin, belonging to a group of medicines called statins, and the other active substance is ezetimibe. Coroswera is a medicine used to reduce the level of total cholesterol, so-called "bad" cholesterol (LDL cholesterol) and fatty substances called triglycerides in the blood. Additionally, Coroswera increases the level of so-called "good" cholesterol (HDL cholesterol). HDL cholesterol is often referred to as "good" because it helps prevent the accumulation of "bad" cholesterol in the arteries and thus protects against heart disease. Coroswera reduces cholesterol levels by acting in two ways: reducing the amount of cholesterol absorbed in the gastrointestinal tract and the amount of cholesterol produced in the body. Coroswera is used in patients for whom diet alone is not enough to maintain a normal cholesterol level. During treatment with this medicine, a cholesterol-lowering diet should be followed at all times. The doctor may prescribe Coroswera if the patient is already taking rosuvastatin and ezetimibe in the same doses as in the combination medicine. If the patient has heart disease, Coroswera reduces the risk of heart attack, stroke, the need for surgical procedures to improve blood flow to the heart, or hospitalization due to chest pain. Coroswera does not help reduce body weight. You should continue taking Coroswera, even if your cholesterol level in the blood is at the right level, because this prevents the cholesterol level from rising againand forming deposits in the arteries. Treatment should be discontinued if the doctor advises it or if the patient becomes pregnant.
If any of the above situations apply to the patient (or the patient has any doubts), they should consult their doctor.
the patient has moderate kidney problems (in case of doubt, consult a doctor);
the patient has abnormal thyroid function;
the patient has experienced recurring or unexplained muscle pain, has a history of muscle disorders, or has had previous muscle problems;
the patient regularly consumes large amounts of alcohol;
the patient is of Asian origin (Japan, China, Philippines, Vietnam, Korea, or India);
the patient is taking other medicines called fibrates to lower cholesterol levels;
if any of the above situations apply to the patient or the patient has any doubts, they should consult their doctor.
Before starting Coroswera, the patient should discuss it with their doctor or pharmacist if:
the patient has kidney problems;
the patient has liver problems;
the patient has experienced recurring or unexplained muscle pain, has a history of muscle disorders, or has had previous muscle problems related to taking other cholesterol-lowering medicines. In case of unexplained muscle pain, especially if accompanied by a feeling of illness or fever, the patient should consult their doctor immediately. The patient should also tell their doctor or pharmacist about persistent muscle weakness;
the patient regularly consumes large amounts of alcohol;
the patient has abnormal thyroid function;
While taking this medicine, the doctor will closely monitor patients with diabetes or at risk of developing it. There is a high risk of developing diabetes if the patient has high levels of sugar and fat in the blood, is overweight, and has high blood pressure. In a small number of people, statins can affect liver function. This is detected by a simple blood test that checks for increased liver enzyme activity. Therefore, the doctor will recommend regular blood tests (liver function test) before and during treatment with Coroswera. Serious skin reactions, including Stevens-Johnson syndrome and drug rash with eosinophilia and systemic symptoms (DRESS), have been reported with rosuvastatin. If any of the symptoms described in section 4 occur, the patient should stop taking Coroswera and consult their doctor immediately.
Coroswera should not be used in children and adolescents under 18 years of age.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take. The patient should inform their doctor about taking any of the following medicines:
The action of these medicines may be altered by Coroswera or they may alter the action of Coroswera.
Coroswera can be taken with or without food.
Coroswera should not be takenif the patient is pregnant or breastfeeding. If the patient becomes pregnant while taking Coroswera, they should stop taking it immediatelyand inform their doctor. While taking Coroswera, the patient should avoid becoming pregnant by using effective methods of contraception. Before taking any medicine, the patient should consult their doctor or pharmacist.
Most people can drive and use machines while taking Coroswera, as it does not affect their ability to drive or use machines. However, some patients may experience dizziness while taking Coroswera. If this occurs, the patient should consult their doctor before attempting to drive or use machines.
If the patient has been diagnosed with intolerance to some sugars, they should consult their doctor before taking Coroswera. The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means it is essentially "sodium-free".
This medicine should always be taken exactly as prescribed by the doctor or pharmacist. If the patient has any doubts, they should consult their doctor or pharmacist.
The recommended dose is one Coroswera tablet once a day, taken orally. The medicine can be taken at any time of day, with or without food. The tablet should be swallowed whole, with a glass of water. The patient should take the medicine at the same time every day.
Coroswera should not be used in children and adolescents.
It is essential to visit the doctor regularly to ensure that the cholesterol level has been achieved and maintained.
If the patient takes more Coroswera than they should, they should contact their doctor or the nearest hospital emergency department, as medical attention may be necessary. If hospitalization or treatment with other medicines is required for another condition, the patient should inform the medical staff that they are taking Coroswera.
If the patient misses a dose, they should take the next tablet at the right time. The patient should not take a double dose to make up for the missed dose.
The patient should tell their doctor if they want to stop taking Coroswera. After stopping Coroswera, the cholesterol level may rise again. If the patient has any further doubts about taking this medicine, they should consult their doctor or pharmacist.
Like all medicines, Coroswera can cause side effects, although not everybody gets them. It is essential for the patient to know what side effects may be associated with taking Coroswera. They are usually mild and disappear after a short time.
if they experience any of the following allergic reactions:
any unusual muscle pain that lasts longer than expected. As with other statins, unpleasant muscle symptoms have been reported in a very small number of people, which can rarely worsen and lead to potentially life-threatening muscle damage called rhabdomyolysis.
sleep disorders, including insomnia and nightmares
sexual disorders
depression
breathing problems, including persistent cough and/or shortness of breath or fever
tendon damage
persistent muscle weakness
liver problems
red, raised rash, sometimes with target-shaped lesions (erythema multiforme)
muscle breakdown
gallstones or gallbladder inflammation (which can cause stomach pain, nausea, vomiting)
myasthenia (a disease that causes general muscle weakness, including in some cases muscles involved in breathing)
myasthenic syndrome (a disease that causes muscle weakness in the eyes)
The patient should talk to their doctor if they experience muscle weakness in their arms or legs, worsening after periods of activity, double vision, or drooping eyelids, difficulty swallowing, or shortness of breath.
If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children. Do not use this medicine after the expiry date stated on the carton after EXP. The expiry date refers to the last day of the month. Store in the original package to protect from light and moisture. There are no special storage temperature requirements. Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines they no longer use. This will help protect the environment.
5 mg + 10 mg: white or almost white, round, slightly convex film-coated tablets with beveled edges, with the inscription "R1" on one side of the tablet. Tablet diameter: approximately 10 mm. 10 mg + 10 mg: light brown-yellow to brown-yellow, round, slightly convex film-coated tablets with beveled edges, with the inscription "R2" on one side of the tablet. Tablet diameter: approximately 10 mm. 15 mg + 10 mg: light pink-orange, round, slightly convex film-coated tablets with beveled edges, with the inscription "R3" on one side of the tablet. Tablet diameter: approximately 10 mm. 20 mg + 10 mg: light pink, round, slightly convex film-coated tablets with beveled edges, with the inscription "R4" on one side of the tablet. Tablet diameter: approximately 10 mm. 40 mg + 10 mg: light gray-violet to gray-violet, round, slightly convex film-coated tablets with beveled edges, with the inscription "R5" on one side of the tablet. Tablet diameter: approximately 10 mm. Coroswera is available in cardboard boxes containing 14, 15, 28, 30, 56, 60, 84, 90, or 98 film-coated tablets in blisters. Not all pack sizes may be marketed.
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany For more information on this medicine, the patient should contact their local representative of the marketing authorization holder: Krka Polska Sp. z o.o., ul. Równoległa 5, 02-235 Warsaw, phone: +48 22 573 75 00. Date of last revision of the leaflet:28.02.2025
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.